WO2009032703A1 - Composés et compositions inhibiteurs de kinase - Google Patents
Composés et compositions inhibiteurs de kinase Download PDFInfo
- Publication number
- WO2009032703A1 WO2009032703A1 PCT/US2008/074490 US2008074490W WO2009032703A1 WO 2009032703 A1 WO2009032703 A1 WO 2009032703A1 US 2008074490 W US2008074490 W US 2008074490W WO 2009032703 A1 WO2009032703 A1 WO 2009032703A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- chloro
- ylamino
- phenylamino
- isopropylsulfonyl
- Prior art date
Links
- 0 C*C1CCN(*)CC1 Chemical compound C*C1CCN(*)CC1 0.000 description 7
- FGDOUMVPHJHSCK-UHFFFAOYSA-N CC(C)Oc1cc(-c2ccncc2)c(C)cc1[N+]([O-])=O Chemical compound CC(C)Oc1cc(-c2ccncc2)c(C)cc1[N+]([O-])=O FGDOUMVPHJHSCK-UHFFFAOYSA-N 0.000 description 1
- CWXBESRGEPLREF-UHFFFAOYSA-N CC(C)Oc1cc(C2CCN(C)CC2)c(C)cc1Nc1nc(Nc(cccc2)c2S(C(C)C)(=O)=O)c(cn[nH]2)c2n1 Chemical compound CC(C)Oc1cc(C2CCN(C)CC2)c(C)cc1Nc1nc(Nc(cccc2)c2S(C(C)C)(=O)=O)c(cn[nH]2)c2n1 CWXBESRGEPLREF-UHFFFAOYSA-N 0.000 description 1
- JYLHFNDDMMSCJB-UHFFFAOYSA-N CC(C)S(c(cccc1)c1Nc1nc(Nc(c(OC)c2)ccc2C(Nc(cc2)ccc2N2CCN(C)CC2)=O)nc(N)c1Cl)(=O)=O Chemical compound CC(C)S(c(cccc1)c1Nc1nc(Nc(c(OC)c2)ccc2C(Nc(cc2)ccc2N2CCN(C)CC2)=O)nc(N)c1Cl)(=O)=O JYLHFNDDMMSCJB-UHFFFAOYSA-N 0.000 description 1
- AVEHTOWOGCAJJX-UHFFFAOYSA-N CN(CC1)CCN1C(CC1)CCN1C(c1ccc(Nc2nc([nH]cc3)c3c(Nc(cccc3)c3S(C)(=O)=O)c2)nc1)=O Chemical compound CN(CC1)CCN1C(CC1)CCN1C(c1ccc(Nc2nc([nH]cc3)c3c(Nc(cccc3)c3S(C)(=O)=O)c2)nc1)=O AVEHTOWOGCAJJX-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- ZKLQIVPPHFQZOK-UHFFFAOYSA-N COCCN1CCCC1 Chemical compound COCCN1CCCC1 ZKLQIVPPHFQZOK-UHFFFAOYSA-N 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N OCCN1CCCC1 Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- Cancer is a disease resulting from an abnormal growth of tissue. Certain cancers have the potential to invade into local tissues and also metastasize to distant organs. This disease can develop in a wide variety of different organs, tissues and cell types. Therefore, the term “cancer” refers to a collection of over a thousand different diseases.
- Anaplastic lymphoma kinase (ALK), a member of the insulin receptor superfamily of receptor tyrosine kinases, has been implicated in oncogenesis in hematopoietic and non- hematopoietic tumors.
- ALK insulin receptor superfamily of receptor tyrosine kinases
- the aberrant expression of full-length ALK receptor proteins has been reported in neuroblastomas and glioblastomas; and ALK fusion proteins have occurred in anaplastic large cell lymphoma.
- the study of ALK fusion proteins has also raised the possibility of new therapeutic treatments for patients with ALK-positive malignancies. (Pulford et al., Cell. MoI. Life Sci. 61:2939-2953 (2004)).
- IGF-I Insulin- like growth factor
- IGF-IR IGF-I receptor
- ROSl c-ros oncogene 1
- ROS a member of the tyrosine kinase insulin receptor gene family
- mitotic assembly checkpoint kinase MPS 1 also known as TTK
- TTK mitotic assembly checkpoint kinase
- Normal cells have multiple redundant mechanisms for arresting in mitosis whereas cancer cells have a heightened dependence on TTK activity.
- the invention relates to novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and their use as pharmaceuticals.
- the invention provides compounds having the Formula (I): pa
- a and B are each independently aryl or heteroaryl, each of which may be optionally substituted with one or more R4 groups;
- Y is -SO2-, -SO2NH-, -NH-SO2-, -NH-C(O)-, -C(O)-NH-, -O-, or -NR2-;
- X is NH, O or S
- Z is N or CH
- Rl is H, C1-C6 alkyl, halo-(Cl-C6 alkyl), C1-C6 cycloalkyl, halo-(Cl-C6 cycloalkyl), heterocyclyl, heterocyclylCl- ⁇ alkyl, aryl, arylCl- ⁇ alkyl, heteroaryl or heteroarylCl- ⁇ alkyl;
- R2 is H, C1-C6 alkyl, halo-(Cl-C6 alkyl), C1-C6 cycloalkyl, halo-(Cl-C6 cycloalkyl), heterocyclyl, heterocyclylCl- ⁇ alkyl, aryl, arylCl- ⁇ alkyl, heteroaryl or heteroarylCl- ⁇ alkyl; R3
- Ra is hydrogen and Rb is halogen, or Ra and Rb, taken together with the atoms to which they are bound form a pyrazolo or a pyrrolo ring fused to the pyrimidine ring, said pyrazolo or pyrrolo ring optionally bearing one or two R4 groups;
- R4 is independently halogen, C1-C6 alkyl, halo-(Cl-C6 alkyl), Cl- C6 cycloalkyl, halo-(Cl-C6 cycloalkyl), heterocyclyl, heterocyclylCl- ⁇ alkyl, aryl, arylCl- ⁇ alkyl, heteroaryl or heteroarylCl- ⁇ alkyl, Cl-6alkoxy, Cl-6alkylthio, hydroxyl, nitro, azido, cyano, acyloxy, carboxy, ester, carbamoyl, carboxamide, ureido, amidino, guanidine, sulfonyl, sulphonylamino, aminosulphonyl;
- R5 is independently is C1-C6 alkoxy, ⁇ — / , hydroxy, ⁇ — N N-(C 1 -C 6 alkyl) , dialkylamino, or -N-R7;
- R6 is independently is hydroxy, ⁇ — ' , Nv — ⁇ , or -
- R7 is independently is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, or C1-C6 hydroxyalkyl;
- R 3 or R 4 if present in B are not nitro, azido, ureido, guanidine or sulphonylamino;
- R 3 or R 4 if present in B are independently halogen, Ci-C 6 alkyl, halo-(d- Ce alkyl), C 3 -C 7 cycloalkyl, halo-(C 3 -C 7 cycloalkyl), heterocyclyl, heterocyclylCi_ 6 alkyl, aryl, arylCi_ 6 alkyl, heteroaryl or heteroarylCi_ 6 alkyl.
- the invention provides compounds having Formula IA or III:
- R 3 is -CO-R 5 , * alternatively, R 3 or R 4 if present in B are independently halogen, Ci-C 6 alkyl, halo-(d-
- Y, X, R 1 , R 2 , R 5 , R 7 , R a and R b are as defined in Formula I.
- the invention provides compounds having Formula III:
- R 3 or R 4 if present in B are independently halogen, Ci-C 6 alkyl, 1IaIo-(C 1 - C 6 alkyl), C 3 -C 7 cycloalkyl, halo-(C 3 -C 7 cycloalkyl), heterocyclyl, heterocyclylCi_ 6 alkyl, aryl, arylCi_ 6 alkyl, heteroaryl or heteroarylCi_ 6 alkyl; n is an integer from 0-3; m is an integer from 0-4; p is an integer from 0-2; and
- Y, X, R 1 , R 2 , R 5 , R 7 are as defined in Formula I.
- the invention encompasses a compound of Formula I, IA, II or III, wherein X is O. In still other embodiments, the invention encompasses a compound of Formula I, IA, II or III, wherein R 2 is methyl, ethyl, propyl, isopropyl, cyclopropyl or cyclobutyl. In yet other embodiments, the invention encompasses a compound of Formula I, IA, II or III, wherein R is methyl. In another embodiment , the invention encompasses a compound of Formula I, IA, II or III, wherein Y is SO 2 .
- the invention encompasses a compound of Formula I, IA, II or III, wherein R 1 is methyl, ethyl, propyl, isopropyl, cyclopropyl or cyclobutyl.
- the invention encompasses a compound of Formula I, IA, II or III, wherein R 1 is isopropyl.
- the invention encompasses a compound of Formula I, IA, II or III, wherein X is O, R 2 is methyl, Y is SO 2 and R 1 is isopropyl.
- the invention provides compounds having Formula I wherein Z is N, and said compound is selected from the group consisting of: methyl 3-(4-amino-5-chloro-6-(2-(methylsulfonyl)phenylamino)pyrimidin-2-ylamino)-4- methoxybenzoate ;
- the invention provides compounds having Formula I wherein Z is CH and said compound is selected from the group consisting of: l-(4-(4-(2-(isopropylsulfonyl)phenylamino)-lH-pyrrolo[2,3-b]pyridin-6-ylamino)-3- methoxyphenyl)piperidin-4-ol;
- the invention provides compounds having Formula (III) and selected from the group consisting of:
- Another aspect of the invention encompasses a pharmaceutical composition
- a pharmaceutical composition comprising a compound according to Formula I, IA, II or III or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof and a pharmaceutically acceptable diluent or carrier.
- the pharmaceutical composition the invention encompasses a composition wherein the compound is present in a therapeutically effective amount.
- the pharmaceutical composition the invention further encompasses at least one further active compound, such as for example, an anti-hyperproliferative agent.
- Another aspect of the invention encompasses a packaged pharmaceutical composition comprising a container, the pharmaceutical composition of the invention and instructions for using the pharmaceutical composition to treat a disease or condition in a mammal.
- Yet another aspect of the invention encompasses a method of inhibiting kinase activity in a cell comprising contacting a cell with one or more compounds of the invention.
- the kinase whose activity is inhibited is anaplastic lymphoma kinase, (ALK) hepatocyte growth factor receptor tyrosine kinase (c-Met), monopolar spindle (Mpsl) kinase, Ros, IGF-IR or InsR kinase.
- ALK activity is inhibited.
- c-Met or Mpsl kinase activity is inhibited.
- the invention also provides methods for treating a condition mediated by ALK, c- Met, Mpsl, Ros, IGFlR or InsR, comprising administering to a cell or tissue system or to a mammalian subject, a therapeutically effective amount of a compound of Formula I, IA, II or III, or pharmaceutically acceptable salts or tautomers thereof, and optionally in combination with a second therapeutic agent; thereby treating said condition mediated by ALK, c-Met, Mpsl, Ros, IGFlR or InsR.
- the compounds of the invention may be used for treating a condition mediated by ALK.
- the present invention provides the use of a compound having Formula I, IA, II or III, in the manufacture of a medicament for treating a condition mediated by ALK, c- Met, Mpsl, Ros, IGFlR or InsR.
- the compounds of the invention may be used alone or in combination with a second therapeutic agent to treat a condition mediated by ALK, c-Met, Mpsl, Ros, IGFlR or InsR, wherein said condition is an autoimmune disease, a transplantation disease, an infectious disease or a cell proliferative disorder.
- the invention provides methods for treating a cell proliferative or angiogenesis disorder, comprising administering to a system or subject in need of such treatment an effective amount of a compound having Formula I, IA, II or III, or pharmaceutically acceptable salts or pharmaceutical compositions thereof, and optionally in combination with a second therapeutic agent, thereby treating said disorder.
- the present invention provides the use of a compound having Formula I, IA, II or III, in the manufacture of a medicament for treating a cell-proliferative or angiogenesis disorder.
- the compounds of the invention may be used alone or in combination with a chemotherapeutic agent to treat a cell proliferative disorder, including but not limited to, multiple myeloma, neuroblastoma, lymphoma, leukemia, melanoma, sarcoma, osteosarcoma, synovial sarcoma, Ewing's sarcoma, hepatoma, gastrointestinal stromal tumor or a solid tumor or cancer of breast, renal, prostate, colorectal, thyroid, ovarian, pancreas, lung, uterus, respiratory tract, brain, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid or parathyroid.
- a chemotherapeutic agent to treat a cell proliferative disorder, including but not limited to, multiple myeloma, neuroblastoma, lymphoma, leukemia, melanoma, sarcoma, osteosarcoma, synovial sarcoma, Ewing'
- a compound having Formula I, IA, II or III may be administered to a system comprising cells or tissues, or to a mammalian subject such as a human or animal subject.
- halogen refers to radicals of fluorine, chlorine, bromine and iodine.
- alkyl refers to a straight or branched hydrocarbon chain radical, containing solely carbon and hydrogen atoms, having in the range from one up to eight carbon atoms, and which is attached to the rest of the molecule by a single bond, such as illustratively, methyl, ethyl, n-propyl 1-methylethyl (iso-propyl), n-butyl, n-pentyl, and 1,1-dimethylethyl (tert-butyl).
- cycloalkyl denotes a non-aromatic mono or multicyclic ring system having in the range of 3 up to 14 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- multicyclic cycloalkyl groups include decahydronapththyl.
- bridged cycloalkyl groups or sprirobicycloalkyl groups include adamantyl norbornyl, and spiro[4.4]nonyl groups.
- Examples of carbocyclic rings include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylene, cyclohexanone, etc.
- alkoxy denotes an alkyl group as defined herein attached via an oxygen linkage to the rest of the molecule. Representative examples of those groups are methoxy, ethoxy, iso-propoxy, n-butoxy, and tert-butoxy.
- cycloalkoxy denotes a cycloalkyl group as defined herein attached via an oxygen linkage to the rest of the molecule. Representative examples of those groups are cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexoxy, and cycloheptoxy.
- aryl refers to aromatic radicals having in the range of 6 up to 14 carbon atoms such as phenyl, naphthyl, indanyl, and biphenyl.
- heteroaryl refers to a stable 5- to 13-membered aromatic heterocycle having in the range of from 1 up to 4 heteroatoms from the group consisting of nitrogen, phosphorus, oxygen and sulfur, which ring or ring system can be linked via a carbon atom or a nitrogen atom, if such an atom is present.
- the heteroaryl ring radical may be a monocyclic, bicyclic or tricyclic ring system.
- heteroaryl radicals examples include: pyridyl, pyridyl N-oxide, pyrimidyl, pyridazinyl, pyrazinyl, thienyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl or isoxazolyl, indolicenyl, indolyl, benzo[b] thienyl, benzo[b]furyl, benzothiazolyl, benzothiadiazolyl, indazolyl, quinolyl, isoquinolyl, isoquinolyl, naphthyridinyl, quinazolinyl, oxadiazolyl, benzoxazolyl, tetrazoyl, triazolyl, thiadiazolyl, and benzimidazolyl.
- heterocycloalkyl refers to a stable 3 to 13 membered saturated or partially unsaturated heterocycle having in the range from 1 up to 4 heteroatoms from the group consisting of nitrogen, phosphorus, oxygen and sulfur, which ring or ring system can be linked via a carbon atom or a nitrogen atom, if such an atom is present.
- the heterocyclic ring radical may be a monocyclic, bicyclic or tricyclic ring system, which may include fused, bridged or spiro ring systems.
- heterocyclyl radicals examples include: tetrahydropyranyl, aziridyl, azepanyl, tetrahydrofuryl, pyrrolidinyl, pyrrolinyl, piperidinyl, 1,2 dihydropyridinyl, 1,4 dihydropyridinyl, piperazinyl, morpholinyl, thiomorpholinyl, azepinyl, oxazolinyl, thiazolinyl and 1,4 diazepinyl.
- nitrogen non-aromatic heterocyclyl radicals include but are not limited to piperidinyl, piperazinyl, pyrrolidinyl, azetidinyl, morpholinyl, etc.
- alkylamino refers to an alkyl group as defined herein attached via amino linkage to the rest of the molecule.
- alkylamino further includes dialkyl amino moieties in which two alkyl groups as define herein are attached via amino linkage to the rest of the molecule. Representative examples of those groups are methylamino and dimethylamino.
- an H atom in any substituent groups encompasses all suitable isotopic variations, e.g., H, 2 H and 3 H.
- a solvate for the purpose of this invention is a complex of a solvent and a compound of the invention in the solid state.
- Exemplary solvates would include, but are not limited to, complexes of a compound of the invention with ethanol or methanol. Hydrates are a specific form of solvate wherein the solvent is water.
- treating or “treatment” as used herein is used conventionally, e.g., the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving the condition of, etc., of a disease or disorder, such as a carcinoma or cancer.
- the present invention is based on the discovery that certain pyrimidine and pyrrolopyridine derivatives possess valuable, pharmacologically useful properties.
- compounds and compositions described herein including salts, metabolites, solvates, solvates of salts, hydrates, prodrugs such as esters, polymorphs, and stereoisomeric forms thereof, may exhibit anti-proliferative activity and are thus useful to prevent or treat the disorders associated with hyper-proliferation.
- the compounds of the invention are effective as protein tyrosine kinase inhibitors.
- the compounds of the invention may inhibit the tyrosine kinase activity of anaplastic lymphoma kinase (ALK) and/or the fusion protein of NPM-ALK .
- ALK anaplastic lymphoma kinase
- NPM-ALK fusion protein of NPM-ALK .
- NPM-ALK plays a key role in signal transmission in a number of hematopoetic and other human cells leading to hematological and neoplastic diseases, for example in anaplastic large-cell lymphoma (ALCL) and non-Hodgkin's lymphomas (NHL), specifically in ALK+NHL or Alkomas, in inflammatory myofibroblastic tumors (IMT) and neuroblastomas.
- ACL anaplastic large-cell lymphoma
- NHL non-Hodgkin's lymphomas
- IMT myofibroblastic tumors
- other gene fusions have been identified in human hematological and neoplastic diseases; mainly TPM3-ALK (a fusion of nonmuscle tropomyosin with ALK).
- EML4- ALK fusion tyrosine kinase generated transformed foci in culture and subcutaneous tumors in mice. Therefore EML4-ALK, which is inhibited by the compounds described in this application, maybe a relevant target for NSCLC patients or other patients with this or related ALK-containing fusion proteins (Nature. 2007 Aug 2;448(7153):561-6)
- the pyrimidine derivatives are useful for the inhibition of all such ALK-containing gene fusions.
- a and B are each independently aryl or heteroaryl, each of which may be optionally substituted with one or more R4 groups;
- Y is -SO2-, -SO2NH-, -NH-SO2-, -NH-C(O)-, -C(O)-NH-, -O-, or -NR2-;
- X is NH, O or S
- Z is N or CH
- Rl is H, C1-C6 alkyl, halo-(Cl-C6 alkyl), C1-C6 cycloalkyl, halo-(Cl-C6 cycloalkyl), heterocyclyl, heterocyclylCl- ⁇ alkyl, aryl, arylCl- ⁇ alkyl, heteroaryl or heteroarylCl- ⁇ alkyl;
- R2 is H, C1-C6 alkyl, halo-(Cl-C6 alkyl), C1-C6 cycloalkyl, halo-(Cl-C6 cycloalkyl), heterocyclyl, heterocyclylCl- ⁇ alkyl, aryl, arylCl- ⁇ alkyl, heteroaryl or heteroarylCl- ⁇ alkyl;
- R3 is R4, -CO-R5,
- Ra is hydrogen and Rb is halogen, or Ra and Rb, taken together with the atoms to which they are bound form a pyrazolo or a pyrrolo ring fused to the pyrimidine ring, said pyrazolo or pyrrolo ring optionally bearing one or two R4 groups;
- R4 is independently halogen, C1-C6 alkyl, halo-(Cl-C6 alkyl), Cl- C6 cycloalkyl, halo-(Cl-C6 cycloalkyl), heterocyclyl, heterocyclylCl- ⁇ alkyl, aryl, arylCl- ⁇ alkyl, heteroaryl or heteroarylCl- ⁇ alkyl, Cl-6alkoxy, Cl-6alkylthio, hydroxyl, nitro, azido, cyano, acyloxy, carboxy, ester, carbamoyl, carboxamide, ureido, amidino, guanidine, sulfonyl, sulphonylamino, aminosulphonyl;
- R5 is independently is C1-C6 alkoxy, ⁇ — / , hydroxy, N N-(C 1 -C 6 alkyl) , dialkylamino, or -N-R7;
- R6 is independently is hydroxy, " ⁇ — ' , ⁇ — ⁇ , or -
- R7 is independently is hydrogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, or C1-C6 hydroxyalkyl;
- -X-R2 and -R3 may each independently represent hydrogen.
- the invention encompasses a compound having the formula IA: wherein: n is an integer from 0-3; m is an integer from 0-4; and Y, X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R a and R b are as defined in Formula I. [0043] In yet another embodiment, the invention encompasses a compound having the formula II:
- the invention encompasses a compound having the formula III:
- Another aspect of the invention encompasses a compound having the IUPAC name: methyl 3-(4-amino-5-chloro-6-(2-(methylsulfonyl)phenylamino)pyrimidin-2-ylamino)-4- methoxybenzoate ;
- Still another aspect of the invention encompasses a compound having the IUPAC name: l-(4-(4-(2-(isopropylsulfonyl)phenylamino)-lH-pyrazolo[3,4-d]pyrimidin-6-ylamino)-3- methoxyphenyl)piperidin-4-ol; l-(3-ethoxy-4-(4-(2-(isopropylsulfonyl)phenylamino)-lH-pyrazolo[3,4-d]pyrimidin-6- ylamino)phenyl)piperidin-4-ol;
- Yet another aspect of the invention encompasses a compound having the IUPAC name: methyl 6-(4-(2-(isopropylsulfonyl)phenylamino)-lH-pyrrolo[2,3-b]pyridin-6- ylamino)nicotinate;
- the compounds of this invention may contain one or more asymmetric centers, depending upon the location and nature of the various substituents desired.
- Asymmetric carbon atoms may be present in the (R) or (S) configuration, resulting in racemic mixtures in the case of a single asymmetric center, and diastereomeric mixtures in the case of multiple asymmetric centers.
- asymmetry may also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds.
- Substituents on a ring may also be present in either cis or trans form. It is intended that all such configurations (including enantiomers and diastereomers), are included within the scope of the present invention.
- the optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers.
- appropriate acids are tartaric, diacetyltartaric, ditoluoyltartaric and camphorsulfonic acid.
- Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known in the art, for example, by chromatography or fractional crystallization.
- the optically active bases or acids are then liberated from the separated diastereomeric salts.
- a different process for separation of optical isomers involves the use of chiral chromatography (e.g., chiral HPLC columns), with or without conventional derivitization, optimally chosen to maximize the separation of the enantiomers.
- Suitable chiral HPLC columns are manufactured by Diacel, e.g., Chiracel OD and Chiracel OJ among many others, all routinely selectable.
- Enzymatic separations, with or without derivitization are also useful.
- the optically active compounds of this invention can likewise be obtained by chiral syntheses utilizing optically active starting materials.
- the present invention also relates to useful forms of the compounds as disclosed herein, such as pharmaceutically acceptable salts, co-precipitates, metabolites, hydrates, solvates and prodrugs of all the compounds of examples.
- pharmaceutically acceptable salt refers to a relatively non-toxic, inorganic or organic acid addition salt of a compound of the present invention. For example, see S. M. Berge, et al. "Pharmaceutical Salts," J. Pharm. Sci. 1977, 66, 1-19.
- Pharmaceutically acceptable salts include those obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methane sulfonic acid, camphor sulfonic acid, oxalic acid, maleic acid, succinic acid and citric acid.
- Pharmaceutically acceptable salts also include those in which the main compound functions as an acid and is reacted with an appropriate base to form, e.g., sodium, potassium, calcium, magnesium, ammonium, and chorine salts.
- acid addition salts of the claimed compounds may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods.
- alkali and alkaline earth metal salts of acidic compounds of the invention are prepared by reacting the compounds of the invention with the appropriate base via a variety of known methods.
- Representative salts of the compounds of this invention include the conventional nontoxic salts and the quaternary ammonium salts which are formed, for example, from inorganic or organic acids or bases by means well known in the art.
- acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cinnamate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2- hydroxyethanesulfonate, itaconate, lactate, maleate, mandelate, methanesul
- Base salts include alkali metal salts such as potassium and sodium salts, alkaline earth metal salts such as calcium and magnesium salts, and ammonium salts with organic bases such as dicyclohexylamine and N-methyl-D-glucamine.
- basic nitrogen containing groups may be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, and dibutyl sulfate; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and strearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.
- lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides
- dialkyl sulfates like dimethyl, diethyl, and dibutyl sulfate
- diamyl sulfates long chain halides such as decyl, lauryl
- the present invention also includes all suitable isotopic variations of the compounds of the invention, or pharmaceutically acceptable salts thereof.
- An isotopic variation of a compound of the invention or a pharmaceutically acceptable salt thereof is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
- isotopes that may be incorporated into the compounds of the invention and pharmaceutically acceptable salts thereof include but are not limited to isotopes of hydrogen, carbon, nitrogen and oxygen such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 17 0, 18 0, 35 S, 18 F, 36 Cl and 123 I.
- Certain isotopic variations of the compounds of the invention and pharmaceutically acceptable salts thereof for example, those in which a radioactive isotope such as 3 H or 14 C is incorporated, are useful in drug and/or substrate tissue distribution studies.
- 3 H and 14 C isotopes may be used for their ease of preparation and detectability.
- substitution with isotopes such as H may afford certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half- life or reduced dosage requirements.
- Isotopic variations of the compounds of the invention or pharmaceutically acceptable salts thereof can generally be prepared by conventional procedures using appropriate isotopic variations of suitable reagents.
- Isotopic variations of the compounds have the potential to change a compound' s metabolic fate and/or create small changes in physical properties such as hydrophobicity, and the like.
- Isotopic variation have the potential to enhance efficacy and safety, enhance bioavailability and half-life, alter protein binding, change biodistribution, increase the proportion of active metabolites and/or decrease the formation of reactive or toxic metabolites.
- each optionally substituted moiety may be substituted with Ci-6 alkyl, C 2 -6 alkenyl or C3-6 alkynyl, each of which may be optionally halogenated or optionally having a carbon that may be replaced or substituted with N, S, O, or a combination thereof (for example, hydroxylCi-Csalkyl, Ci-CsalkoxyCi-Csalkyl); halo, amino, amidino, Ci_ 6 alkoxy; hydroxyl, methylenedioxy, carboxy; C 1-8 alkylcarbonyl, C 1-8 alkoxycarbonyl, carbamoyl, Ci_ 8 alkylcarbamoyl, sulfamoyl, cyano, oxo, nitro, or an optionally substituted carbocyclic ring, heterocyclic ring, aryl or heteroaryl as previously described.
- the compounds of the invention may be selectively toxic or more toxic to rapidly proliferating cells than to normal cells, and may be used to treat hyper-proliferative disorders.
- the compounds of the invention may have significant antiproliferative effects in human cancer cells, e.g., cancerous tumors, and promote differentiation, e.g., cell cycle arrest and apoptosis.
- the compounds of the invention may be utilized to inhibit, block, reduce or decrease cell proliferation and/or cell division, and/or produce apoptosis.
- the method comprises administering to a mammal in need thereof, including a human, an amount of a compound of this invention, or a pharmaceutically acceptable salt, isomer, polymorph, metabolite, hydrate, solvate or ester thereof; etc. which is effective to treat the disorder.
- Hyper-proliferative disorders include but are not limited, e.g., psoriasis, keloids, and other hyperplasias affecting the skin, benign prostate hyperplasia (BPH), solid tumors, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases.
- BPH benign prostate hyperplasia
- solid tumors such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases.
- Those disorders also include lymphomas, sarcomas, and leukemias. These disorders have been well characterized in humans, but also exist with a similar etiology in other mammals, and can be treated by administering pharmaceutical compositions of the present invention.
- breast cancer examples include, but are not limited to invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ.
- cancers of the respiratory tract include, but are not limited to small-cell and non-small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.
- brain cancers include, but are not limited to brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumor.
- Tumors of the male reproductive organs include, but are not limited to prostate and testicular cancer.
- Tumors of the female reproductive organs include, but are not limited to endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus.
- Tumors of the digestive tract include, but are not limited to anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small-intestine, and salivary gland cancers.
- Tumors of the urinary tract include, but are not limited to bladder, penile, kidney, renal pelvis, ureter, urethral and human papillary renal cancers.
- Eye cancers include, but are not limited to intraocular melanoma and retinoblastoma.
- liver cancers include, but are not limited to hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular cholangiocarcinoma.
- Skin cancers include, but are not limited to squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.
- Head-and-neck cancers include, but are not limited to laryngeal, hypopharyngeal, nasopharyngeal, oropharyngeal cancer, lip and oral cavity cancer and squamous cell.
- Lymphomas include, but are not limited to AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Burkitt lymphoma, Hodgkin' s disease, and lymphoma of the central nervous system.
- Sarcomas include, but are not limited to sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.
- Leukemias include, but are not limited to acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia.
- the present invention also provides methods for the treatment of disorders associated with aberrant expression of Ros, IGFlR, InsR, ALK, Hepatocyte growth factor receptor tyrosine kinase (c-Met), and/or Nucleophosmin-ALK.
- the compounds described in this application are ATP-competitive kinase inhibitors. As such they competitively block ATP from binding to the kinase active site and thereby prevent phosphorylation of downstream substrates. This effectively blocks signal transduction from the targeted kinases.
- Compounds in this application have the potential to interact with any kinase in the human kinome and have been tested for their ability to bind to a panel of 320 distinct protein kinases.
- This panel includes the following kinases: AAKl, ABLl, ABL1(E255K), ABL1(H396P), ABL1(M351T), ABL1(Q252H), ABL1(T315I), ABL1(Y253F), AB L2, ACVRl, ACVRlB, ACVR2A, ACVR2B, ACVRLl, ADCK3,ADCK4,AKT1,AKT2, AKT3,ALK,AMPK-alphal,AMPK-alpha2, ANKKl, ARK5, AURKA, AURKB, AURKC, AXL, BIKE, BLK, BMPRlA, BMPR2, BMX, BRAF, BRAF(V600E), BRSKl, BRS K2, BTK, CAMKl, CAMKlD, CAMKlG, CAMK2A, CAMK2B, CAMK2D, CAMK2G, CAMK4, CAMKKl, CAMKK2, CDC2L
- the compounds of the invention demonstrate inhibitory activity against: ADCK3, ADCK4, ALK, CLKl, CLK4, EGFR, EGFR(E746-A750del), EGFR(L747-E749del, A750P), EGFR(L747-S752del, P753S), EGFR(L747-T751del,Sins), EGFR(L858R), EGFR(L861Q), EGFR(S752-I759del), ERBB4, FER, FES, GAK, IGFlR, INSR, INSRR, LTK, PTK2, PTK2B, ROSl, RPS6KAl(Kin.Dom.2), TNKl, TNK2, TTK.
- the ALK inhibitory activity and inhibitory activity against ALK-containing gene fusions of the compounds described herein make them useful pharmaceutical agents for the treatment of proliferative diseases.
- the inventive compounds are particularly useful for treating a tumor which is a breast cancer, genitourinary cancer, lung cancer, gastrointestinal cancer, epidermoid cancer, melanoma, ovarian cancer, pancreas cancer, neuroblastoma, head and/or neck cancer or bladder cancer, or in a broader sense renal, brain or gastric cancer; in particular (i) a breast tumor; an epidermoid tumor, such as an epidermoid head and/or neck tumor or a mouth tumor; a lung tumor, for example a small cell or non-small cell lung tumor; a gastrointestinal tumor, for example, a colorectal tumor; or a genitourinary tumor, for example, a prostate tumor (especially a hormone-refractory prostate tumor); or (ii) a proliferative disease that is refractory to the treatment with
- a proliferative disease may furthermore be a hyperproliferative condition such as leukemias, hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.
- a hyperproliferative condition such as leukemias, hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty.
- Proliferative diseases treated according to the present method include tumors of blood and lymphatic system (e.g.
- lymphoid leukemia acute or chronic myeloid leukemia, acute or chronic lymphocytic leukemia, monocytic leukemia, other leukemias of specified cell type, leukemia of unspecified cell type, other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissues, for example diffuse large cell lymphoma, T-cell lymphoma or cutaneous T-cell lymphoma).
- Myeloid cancer includes e.g. acute or chronic myeloid leukaemia.
- the present invention also provides methods of treating disorders and diseases associated with aberrant expression of the neurotrophic growth factor receptor tyrosine kinase A, B and C (Trk A, B, C also known as NTRKl, 2, and 3).
- the compounds in the present invention exhibit inhibition of the neurotrophic growth factor receptor tyrosine kinase A, B and C (Trk A, B, C also known as NTRKl, 2, and 3).
- Nrk A, B, C also known as NTRKl, 2, and 3
- Several lines of evidence have implicated NTRKs in the development and progression of cancer through deregulation of tyrosine kinase activity by mutations, chromosomal rearrangements, upregulation of either the receptor, their ligand (Nerve Growth Factor, Brain Derived Neurotropic Factor, Neurotrophins) or both. Chromosomal translocations involving both NTRKl & 3 have been found in several different types of tumors.
- TrkB is of central importance in preventing anoikis (detachment-induced apoptosis) which is believed to an important requirement in the metastatic process.
- the present invention also provides methods of treating disorders and diseases associated with excessive and/or abnormal angiogenesis.
- Inappropriate and ectopic expression of angiogenesis can be deleterious to an organism.
- a number of pathological conditions are associated with the growth of extraneous blood vessels. These include, e.g., diabetic retinopathy, ischemic retinal-vein occlusion, and retinopathy of prematurity (Aiello et al. New Engl. J. Med. 1994, 331, 1480; Peer et al. Lab. Invest. 1995, 72, 638), age-related macular degeneration (AMD; see, Lopez et al. Invest. Opththalmol. Vis. Sci.
- neovascular glaucoma neovascular glaucoma, psoriasis, retrolental fibroplasias, angiofibroma, inflammation, rheumatoid arthritis (RA), restenosis, in-stent restenosis, vascular graft restenosis, etc.
- RA rheumatoid arthritis
- restenosis in-stent restenosis
- vascular graft restenosis etc.
- the increased blood supply associated with cancerous and neoplastic tissue encourages growth, leading to rapid tumor enlargement and metastasis.
- the growth of new blood and lymph vessels in a tumor provides an escape route for renegade cells, encouraging metastasis and the consequence spread of the cancer.
- compounds of the present invention can be utilized to treat and/or prevent any of the aforementioned angiogenesis disorders, e.g., by inhibiting and/or reducing blood vessel formation; by inhibiting, blocking, reducing, decreasing, etc. endothelial cell proliferation or other types involved in angiogenesis, as well as causing cell death or apoptosis of such cell types.
- the effective dosage of the compounds of this invention can readily be determined for treatment of each desired indication.
- the amount of the active ingredient to be administered in the treatment of one of these conditions can vary widely according to such considerations as the particular compound and dosage unit employed, the mode of administration, the period of treatment, the age and sex of the patient treated, and the nature and extent of the condition treated.
- the total amount of the active ingredient to be administered will generally range from about 0.001 mg/kg to about 200 mg/kg body weight per day, and preferably from about 0.01 mg/kg to about 20 mg/kg body weight per day.
- the average daily oral dosing will be from about 200 mg/day to about 600 mg/day which corresponds to 2.8-8.6 mg/kg for a person with an average weight of 70 kgs.
- Clinically useful dosing schedules will range from one to three times a day dosing to once every four weeks dosing.
- "drug holidays" in which a patient is not dosed with a drug for a certain period of time may be beneficial to the overall balance between pharmacological effect and tolerability.
- a unit dosage may contain from about 0.5 mg to about 1500 mg of active ingredient, and can be administered one or more times per day or less than once a day.
- the average daily dosage for administration by injection including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/kg of total body weight.
- the average daily rectal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight.
- the average daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight.
- the average daily topical dosage regimen will preferably be from 0.1 to 200 mg administered between one to four times daily.
- the transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/kg.
- the average daily inhalation dosage regimen will preferably be from 0.01 to 100 mg/kg of total body weight.
- the specific initial and continuing dosage regimen for each patient will vary according to the nature and severity of the condition as determined by the attending diagnostician, the activity of the specific compound employed, the age and general condition of the patient, time of administration, route of administration, rate of excretion of the drug, drug combinations, and the like.
- the desired mode of treatment and number of doses of a compound of the present invention or a pharmaceutically acceptable salt or ester or composition thereof can be ascertained by those skilled in the art using conventional treatment tests.
- the compounds of this invention can be administered as the sole pharmaceutical agent or in combination with one or more other pharmaceutical agents where the combination causes no unacceptable adverse effects.
- the compounds of this invention can be combined with known anti-hyper-proliferative or other indication agents, and the like, as well as with admixtures and combinations thereof.
- the additional pharmaceutical agent can be aldesleukin, alendronic acid, alfaferone, alitretinoin, allopurinol, aloprim, aloxi, altretamine, aminoglutethimide, amifostine, amrubicin, amsacrine, anastrozole, anzmet, aranesp, arglabin, arsenic trioxide, aromasin, 5-azacytidine, azathioprine, BCG or tice BCG, bestatin, betamethasone acetate, betamethasone sodium phosphate, bexarotene, bleomycin sulfate, broxuridine , bortezomib, busulfan, calcitonin, campath, capecitabine, carboplatin, casodex, cefesone, celmoleukin, cerubidine, chlorambucil, cisplatin, cladribine, cladribine, clo
- Optional anti-hyper-proliferative agents which can be added to the composition include but are not limited to compounds listed on the cancer chemotherapy drug regimens in the 11 th Edition of the Merck Index, (1996), which is hereby incorporated by reference, such as asparaginase, bleomycin, carboplatin, carmustine, chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, doxorubicin (adriamycine), epirubicin, etoposide, 5-fluorouracil, hexamethylmelamine, hydroxyurea, ifosfamide, irinotecan, leucovorin, lomustine, mechlorethamine, 6-mercaptopurine, mesna, methotrexate, mitomycin C, mitoxantrone, prednisolone, pred
- composition of the invention include but are not limited to those compounds acknowledged to be used in the treatment of neoplastic diseases in Goodman and Gilman's The Pharmacological Basis of Therapeutics (Ninth Edition), editor Molinoff et al., publ.
- anti-hyper-proliferative agents suitable for use with the composition of the invention include but are not limited to other anti-cancer agents such as epothilone and its derivatives, irinotecan, raloxifen and topotecan. Dosage Forms and Modes of Administration
- compounds of the invention will be administered in therapeutically effective amounts via any of the usual and acceptable modes known in the art, either singly or in combination with one or more therapeutic agents.
- a therapeutically effective amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors known to those of ordinary skill in the art.
- the required dosage will also vary depending on the mode of administration, the particular condition to be treated and the effect desired.
- compositions comprising them that are suitable for oral administration can be presented as discrete dosage forms, such as, but are not limited to, tablets (e.g., chewable tablets), caplets, capsules, and liquids (e.g., flavored syrups).
- dosage forms contain predetermined amounts of active ingredients, and may be prepared by methods of pharmacy well known to those skilled in the art. See generally, Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton Pa. (1990).
- Typical oral dosage forms of the invention are prepared by combining the active ingredient(s) in an intimate admixture with at least one excipient according to conventional pharmaceutical compounding techniques.
- Excipients can take a wide variety of forms depending on the form of preparation desired for administration.
- excipients suitable for use in oral liquid or aerosol dosage forms include, but are not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and coloring agents.
- excipients suitable for use in solid oral dosage forms include, but are not limited to, starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents.
- tablets and capsules represent very advantageous oral dosage unit forms, in which case solid excipients are employed. If desired, tablets can be coated by standard aqueous or nonaqueous techniques. Such dosage forms can be prepared by any of the methods of pharmacy. In general, pharmaceutical compositions and dosage forms are prepared by uniformly and intimately admixing the active ingredients with liquid carriers, finely divided solid carriers, or both, and then shaping the product into the desired presentation if necessary.
- a tablet can be prepared by compression or molding. Compressed tablets can be prepared by compressing in a suitable machine the active ingredients in a free- flowing form such as powder or granules, optionally mixed with an excipient. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- excipients that can be used in oral dosage forms of the invention include, but are not limited to, binders, fillers, disintegrants, and lubricants.
- Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, (e.g., nos. 2208, 2906, 2910), microcrystalline cellulose, and mixtures thereof.
- fillers suitable for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.
- the binder or filler in pharmaceutical compositions of the invention is typically present in from about 50 to about 99 weight percent of the pharmaceutical composition or dosage form.
- Suitable forms of microcrystalline cellulose include, but are not limited to, the materials sold as AVICEL-PH- 101, AVICEL-PH- 103 AVICEL RC-581, AVICEL-PH- 105 (available from FMC Corporation, American Viscose Division, Avicel Sales, Marcus Hook, Pa.), and mixtures thereof.
- An specific binder is a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose sold as AVICEL RC-581.
- Suitable anhydrous or low moisture excipients or additives include AVICEL-PH- 103.TM and Starch 1500 LM.
- Disintegrants are used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment. Tablets that contain too much disintegrant may disintegrate in storage, while those that contain too little may not disintegrate at a desired rate or under the desired conditions. Thus, a sufficient amount of disintegrant that is neither too much nor too little to detrimentally alter the release of the active ingredients should be used to form solid oral dosage forms of the invention.
- the amount of disintegrant used varies based upon the type of formulation, and is readily discernible to those of ordinary skill in the art. Typical pharmaceutical compositions comprise from about 0.5 to about 15 weight percent of disintegrant, specifically from about 1 to about 5 weight percent of disintegrant.
- Disintegrants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums, and mixtures thereof.
- Lubricants that can be used in pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, and mixtures thereof.
- calcium stearate e.g., magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc
- hydrogenated vegetable oil e.g., peanut oil, cottonseed oil
- Additional lubricants include, for example, a syloid silica gel (AEROSIL 200, manufactured by W. R. Grace Co. of Baltimore, Md.), a coagulated aerosol of synthetic silica (marketed by Degussa Co. of Piano, Tex.), CAB-O-SIL (a pyrogenic silicon dioxide product sold by Cabot Co. of Boston, Mass.), and mixtures thereof. If used at all, lubricants are typically used in an amount of less than about 1 weight percent of the pharmaceutical compositions or dosage forms into which they are incorporated.
- AEROSIL 200 a syloid silica gel
- a coagulated aerosol of synthetic silica marketed by Degussa Co. of Piano, Tex.
- CAB-O-SIL a pyrogenic silicon dioxide product sold by Cabot Co. of Boston, Mass.
- Parenteral dosage forms can be administered to patients by various routes including, but not limited to, subcutaneous, intravenous (including bolus injection and constant infusion), intramuscular, and intraarterial. Because their administration typically bypasses patients' natural defenses against contaminants, parenteral dosage forms are preferably sterile or capable of being sterilized prior to administration to a patient. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products (including, but not limited to lyophilized powders, pellets, and tablets) ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions.
- Suitable vehicles that can be used to provide parenteral dosage forms of the invention are well known to those skilled in the art. Examples include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate. Compounds that increase the solubility of one or more of the active ingredients disclosed herein can also be incorporated into the parenteral dosage forms of the invention.
- Transdermal, Topical, And Mucosal Dosage Forms include, but are not limited to, ophthalmic solutions, sprays, aerosols, creams, lotions, ointments, gels, solutions, emulsions, suspensions, or other forms known to one of skill in the art. See, e.g., Remington's Pharmaceutical Sciences, 16th and 18th eds., Mack Publishing, Easton Pa. (1980 & 1990); and Introduction to Pharmaceutical Dosage Forms, 4th ed., Lea & Febiger, Philadelphia (1985).
- transdermal dosage forms suitable for treating mucosal tissues within the oral cavity can be formulated as mouthwashes or as oral gels.
- transdermal dosage forms include "reservoir type” or “matrix type” patches, which can be applied to the skin and worn for a specific period of time to permit the penetration of a desired amount of active ingredients.
- Suitable excipients e.g., carriers and diluents
- other materials that can be used to provide transdermal, topical, and mucosal dosage forms encompassed by this invention are well known to those skilled in the pharmaceutical arts, and depend on the particular tissue to which a given pharmaceutical composition or dosage form will be applied.
- excipients include, but are not limited to, water, acetone, ethanol, ethylene glycol, propylene glycol, butane-l,3-diol, isopropyl myristate, isopropyl palmitate, mineral oil, and mixtures thereof to form lotions, tinctures, creams, emulsions, gels or ointments, which are nontoxic and pharmaceutically acceptable.
- Moisturizers or humectants can also be added to pharmaceutical compositions and dosage forms if desired. Examples of such additional ingredients are well known in the art. See, e.g., Remington's Pharmaceutical Sciences, 16th and 18th eds., Mack Publishing, Easton Pa. (1980 & 1990).
- penetration enhancers can be used to assist in delivering the active ingredients to the tissue.
- Suitable penetration enhancers include, but are not limited to: acetone; various alcohols such as ethanol, oleyl, and tetrahydrofuryl; alkyl sulfoxides such as dimethyl sulfoxide; dimethyl acetamide; dimethyl formamide; polyethylene glycol; pyrrolidones such as polyvinylpyrrolidone; Kollidon grades (Povidone, Polyvidone); urea; and various water-soluble or insoluble sugar esters such as Tween 80 (polysorbate 80) and Span 60 (sorbitan monostearate).
- the pH of a pharmaceutical composition or dosage form, or of the tissue to which the pharmaceutical composition or dosage form is applied may also be adjusted to improve delivery of one or more active ingredients.
- the polarity of a solvent carrier, its ionic strength, or tonicity can be adjusted to improve delivery.
- Compounds such as stearates can also be added to pharmaceutical compositions or dosage forms to advantageously alter the hydrophilicity or lipophilicity of one or more active ingredients so as to improve delivery.
- stearates can serve as a lipid vehicle for the formulation, as an emulsifying agent or surfactant, and as a delivery-enhancing or penetration-enhancing agent.
- Different salts, hydrates or solvates of the active ingredients can be used to further adjust the properties of the resulting composition.
- kits which, when used by the medical practitioner, can simplify the administration of appropriate amounts of active ingredients to a patient.
- a typical kit of the invention comprises one or more unit dosage forms of a compound of the invention or one or more compositions comprising a compound of the invention, or physiologically acceptable salts thereof, and instructions for use.
- Kits of the invention can further comprise devices that are used to administer a compound of the invention to a patient.
- devices include, but are not limited to, intravenous cannulation devices, syringes, drip bags, patches, topical gels, pumps, tubing, containers that provide protection from photodegredation, and inhalers.
- Kits of the invention can further comprise pharmaceutically acceptable vehicles that can be used to administer one or more active ingredients.
- the kit can comprise a sealed container of a suitable vehicle in which the active ingredient can be dissolved to form a particulate-free sterile solution that is suitable for parenteral administration.
- Examples of pharmaceutically acceptable vehicles include, but are not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
- aqueous vehicles such as, but not limited to, Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, and Lactated Ringer's Injection
- water-miscible vehicles such as, but not limited to, ethyl alcohol
- the compounds of Formula I, particularly Formula IA can be prepared through the preparation shown in the Reaction Scheme 2 below.
- a sealed tube was charged with 2,3,5,6-tetrachloropyrimidine (2.18 g, 10.03 mmol), 2-(isopropylsulfonyl)benzenamine (2.0 mg, 10.03 mmol), 4N HC1 dioxane (2.5 mL) and dioxane (50.0 mL).
- the tube was sealed and the reaction mixture was stirred at 120 0 C for 24 hours.
- the reaction mixture was then partitioned between ethyl acetate and water. The organic layer was separated and the aqueous layer was neutralized with satd. ⁇ aHC ⁇ 3 solution and extracted with ethyl acetate.
- reaction mixture was poured into ice water and the resulting white solid was filtered and dried, yielding (560 mg) mixture of two isomers 2,5- dichloro-N 4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-4,6-diamine and 5,6-dichloro-N 4 -(2- (isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine.
- the compounds of Formula I, particularly Formula IA can be prepared through the preparation shown in the Reaction Scheme 3 below.
- the compounds of Formula I may be prepared through the preparation of intermediates shown in the Reaction Scheme 4 below aq.)
- This white solid was suspended in water (35 mL) and treated with sat. K 2 CO 3 slowly until a substantial amount of white solid precipitated. This slurry mixture was slowly stirred overnight and then cooled down to 0 0 C. The resulting white solid was collected, washed with water and then dried to give 5.2 g (58% yield) of the title product.
- the reaction mixture was degassed using Argon for 10 min and then Pd 2 (dba) 2 (196 mg, 0.214 mmol) and 2- dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (153 mg, 0.32 mmol) were added.
- the reaction flask was placed into the preheated oil-bath at 100 0 C.
- the reaction mixture was further stirred at 100 0 C for a period of 4 hours after which, it was filtered and partitioned between ethyl acetate and water. The organic layer was separated and the aqueous layer was extracted with ethyl acetate.
- the reaction mixture was degassed using Argon for 10 min after which Pd 2 (dba) 2 (26 mg, 0.03 mmol) and 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (22 mg, 0.05 mmol) were added.
- the reaction flask was put into the preheated oil-bath at 100 0 C.
- the reaction mixture was further stirred at 100 0 C for a period of 6 hours after which, it was filtered and partitioned between ethyl acetate and water. The organic layer was separated and the aqueous layer was extracted with ethyl acetate.
- the reaction mixture was stirred for 6h after which, it was neutralized with IN HCl solution and partitioned between ethyl acetate and water. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic extracts were washed with brine, dried over MgSO 4 , filtered and concentrated. The crude product was used without further purification.
- a microwave tube was charged with 6-chloro-N-(2-(isopropylsulfonyl)pheny I)-I- (tetrahydro-2H-pyran-2-yl)-lH-pyrazolo[3,4-d]pyrimidin-4-amine (40 mg, 0.0917 mmol), 2- isopropoxy-5-methyl-4-(l-methylpiperidin-4-yl)benzenamine (72.3 mg, 0.275 mmol) 4N HCl in Dioxane (0.069 mL, 0.276 mmol) and ethylene glycol (1.5 mL). The tube was sealed and the reaction mixture was stirred at 180 0 C for 30 min in a microwave reactor.
- the reaction mixture was purified by reverse-phase preparative HPLC.
- the crude TFA salt of product was neutralized with a satd. aqueous solution of NaHC ⁇ 3 and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered and concentrated. The residue was purified by flash chromatography using 30:1:0.3 methylene chloride-methanol-triethylamine as solvent to afford the title compound (20.0 mg, 0.037 mmol).
- Murine pro-B cell line Ba/F3 the human t(2,5)-positive Karpas-299 and TEL-ALK transformed Ba/F3 are maintained in RPMI medium 1640 supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO). Ba/F3 cells are grown in the presence of 10% of WEHI media. Cell lines expressing luciferase alone or in combination with TEL-kinase fusion constructs are generated by retroviral transduction of cells with pMSCV-IRES puro/Luc vector.
- Luciferase-expressing Ba/F3 cells, Karpas-299, Tel_ALK transformed Ba/F3 stably expressing NPM-ALK and TEL-ALK are plated in 384-well plates (5,000 cells per well) and incubated with serial dilutions of ALK inhibitors or DMSO for 48 hours. Luciferase expression is used as a measure of cell proliferation/ survival and was evaluated with the Bright-Glo Luciferase Assay System (Promega, Madison, WI). Fifty percent inhibition values (IC 50 ) are generated by using XLFit software.
- mice with established lymphomas are administered vehicle solution or test compound (typically 10 mg/kg) for 3 days.
- test compound typically 10 mg/kg
- ALK tyrosine kinase activity may also be measured using known methods, for example using the recombinant kinase domain of the ALK in analogy to the VEGF-R kinase assay described in J. Wood et al. Cancer Res. 60, 2178-2189 (2000).
- the antiproliferative action of the compounds of the invention can also be determined in the human KARPAS-299 lymphoma cell line (described in WG Dirks et al. Int. J. Cancer 100, 49-56 (2002) using the same methodology described above).
- Compounds 1-3, 1-13, 1-14, 2-1, 2-4, 2-7, 2-10, 2-14, 2-15, 3-14, 5-1, 5-7, 5-8, 5-9, 5-10, 5-11, 5-14, 6-1, 6-2, 6-5, 6-6, 6-9, 6-16, 6-18 are representative examples of inhibitors of NPM-ALK dependent cellular proliferation EC50's of 1 uM or less.
- a cell-based assay consists of using a ETV6-NTRK3 transformed Ba/F3 cell line. This cell line may be used to discover compounds that are differentially cytotoxic as compared to parental Ba/F3 cells grown in the presence of IL-3. Compounds that are selectively cytotoxic to Ba/F3 ETV6-NTRK3 are confirmed using a biochemical NTRK3 kinase assay. Cellular inhibition of NTRK3 is confirmed using phosphospecific antibodies.
- WO 2005016894 - Garcia-echeverria, Carlos; Kanazawa, Takanori; Kawahara, Eiji; Masuya, Keiichi; Matsuura, Naoko; Miyake, Takahiro; Ohmori, Osamu; Umemura, Ichiro; Steensma, Ruo; Chopiuk, Greg; Jiang, Jiqing; Wan, Yongqin; Ding, Qiang; Zhang, Qiong; Gray, Nathanael Schiander; Karanewsky, Donald. Preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. PCT Int. Appl. (2005), 285 pp.
Abstract
Cette invention concerne de nouveaux composés de pyrimidine substituée par des groupes amino, des compositions pharmaceutiques contenant ces composés, et l'utilisation de ces composés ou compositions pour traiter des troubles hyperprolifératifs et/ou d'angiogenèse, en tant qu'agent unique ou en combinaison avec d'autres ingrédients actifs.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96644907P | 2007-08-28 | 2007-08-28 | |
US60/966,449 | 2007-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009032703A1 true WO2009032703A1 (fr) | 2009-03-12 |
Family
ID=40111042
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/074472 WO2009032694A1 (fr) | 2007-08-28 | 2008-08-27 | Pyrimidine substituée par amino, dérivés de pyrollopyridine et de pyrazolopyrimidine utilisés en tant qu'inhibiteurs de la kinase et dans le traitement de troubles prolifératifs et de maladies liées à l'angiogenèse |
PCT/US2008/074490 WO2009032703A1 (fr) | 2007-08-28 | 2008-08-27 | Composés et compositions inhibiteurs de kinase |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/074472 WO2009032694A1 (fr) | 2007-08-28 | 2008-08-27 | Pyrimidine substituée par amino, dérivés de pyrollopyridine et de pyrazolopyrimidine utilisés en tant qu'inhibiteurs de la kinase et dans le traitement de troubles prolifératifs et de maladies liées à l'angiogenèse |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2008296479A1 (fr) |
WO (2) | WO2009032694A1 (fr) |
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010007756A1 (fr) * | 2008-07-14 | 2010-01-21 | 塩野義製薬株式会社 | Dérivé de pyridine ayant une activité d'inhibition de la ttk |
WO2010128659A1 (fr) | 2009-05-08 | 2010-11-11 | アステラス製薬株式会社 | Composé de carboxamide hétérocyclique diamino |
US8039479B2 (en) | 2006-12-08 | 2011-10-18 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
CN102746308A (zh) * | 2012-07-09 | 2012-10-24 | 四川大学 | 别嘌醇衍生物及其制备方法和用途 |
US8318702B2 (en) | 2007-07-06 | 2012-11-27 | Astellas Pharma Inc. | Di(arylamino)aryl compounds |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8450335B2 (en) | 2008-06-27 | 2013-05-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8563568B2 (en) | 2010-08-10 | 2013-10-22 | Celgene Avilomics Research, Inc. | Besylate salt of a BTK inhibitor |
WO2014006554A1 (fr) | 2012-07-03 | 2014-01-09 | Aurigene Discovery Technologies Limited | Dérivés de 3-(pyrazolyl)-1h-pyrrolo[2,3-b]pyridine en tant qu'inhibiteurs de kinase |
US8685988B2 (en) | 2012-08-06 | 2014-04-01 | Acea Biosciences, Inc. | EGFR modulators and uses thereof |
US8796255B2 (en) | 2010-11-10 | 2014-08-05 | Celgene Avilomics Research, Inc | Mutant-selective EGFR inhibitors and uses thereof |
US8975249B2 (en) | 2010-11-01 | 2015-03-10 | Celgene Avilomics Research, Inc. | Heterocyclic compounds and uses thereof |
US9012462B2 (en) | 2008-05-21 | 2015-04-21 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
US9056839B2 (en) | 2012-03-15 | 2015-06-16 | Celgene Avilomics Research, Inc. | Solid forms of an epidermal growth factor receptor kinase inhibitor |
US9108927B2 (en) | 2012-03-15 | 2015-08-18 | Celgene Avilomics Research, Inc. | Salts of an epidermal growth factor receptor kinase inhibitor |
US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US9145387B2 (en) | 2013-02-08 | 2015-09-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US9206166B2 (en) | 2012-11-06 | 2015-12-08 | SHANGHAI iNSTITUTE OF MATERIA MEDICA ACADEMY OF SCIENCES | Certain protein kinase inhibitors |
US9238629B2 (en) | 2010-11-01 | 2016-01-19 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
US9364476B2 (en) | 2011-10-28 | 2016-06-14 | Celgene Avilomics Research, Inc. | Methods of treating a Bruton's Tyrosine Kinase disease or disorder |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
US9586965B2 (en) | 2012-01-13 | 2017-03-07 | Acea Biosciences Inc. | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US9834571B2 (en) | 2012-05-05 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
WO2018021826A1 (fr) * | 2016-07-26 | 2018-02-01 | 한국화학연구원 | Nouveau dérivé de pyrimidine-2,4-diamine et composition pharmaceutique pour la prévention ou le traitement du cancer contenant celui-ci comme ingrédient actif |
US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
US20180244676A1 (en) * | 2015-02-13 | 2018-08-30 | Dana-Farber Cancer Institute, Inc. | Lrrk2 inhibitors and methods of making and using the same |
CN108473490A (zh) * | 2015-12-21 | 2018-08-31 | 癌症研究科技有限公司 | 新型吡咯并[3,2-c]吡啶-6-氨基衍生物 |
KR101896568B1 (ko) * | 2017-03-23 | 2018-09-10 | 재단법인 대구경북첨단의료산업진흥재단 | 피롤로-피리딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
WO2018183112A1 (fr) * | 2017-03-27 | 2018-10-04 | Cardurion Pharmaceuticals, Llc | Composé hétérocyclique |
US20190106422A1 (en) * | 2014-11-06 | 2019-04-11 | Ohio State Innovation Foundation | Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors |
WO2019112344A1 (fr) * | 2017-12-07 | 2019-06-13 | 주식회사 온코빅스 | Nouveau dérivé de pyrimidine ayant pour effet d'inhiber la croissance de cellules cancéreuses, et composition pharmaceutique contenant celui-ci |
US10533011B2 (en) | 2015-10-09 | 2020-01-14 | ACEA Therapeutics, Inc. | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
US10562918B2 (en) | 2013-07-11 | 2020-02-18 | ACEA Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
US10577344B2 (en) | 2013-09-10 | 2020-03-03 | The Board Of Regents Of The University Of Texas System | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins |
US10596174B2 (en) | 2012-01-13 | 2020-03-24 | ACEA Therapeutics, Inc. | Pyrrolopyrimidine compounds as inhibitors of protein kinases |
CN111386266A (zh) * | 2017-12-07 | 2020-07-07 | 昂科比克斯有限公司 | 具有抑制癌细胞生长作用的新型嘧啶衍生物及包含其的药物组合物 |
CN111484484A (zh) * | 2020-04-13 | 2020-08-04 | 沈阳药科大学 | 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用 |
CN112125884A (zh) * | 2010-12-17 | 2020-12-25 | 诺华股份有限公司 | 制备嘧啶-2,4-二胺二盐酸盐的方法 |
US11130752B2 (en) | 2018-09-25 | 2021-09-28 | Cardurion Pharmaceuticals, Llc | Aminopyrimidine compound |
US11208696B2 (en) | 2015-04-17 | 2021-12-28 | Netherlands Translational Research Center B.V. | Prognostic biomarkers for TTK inhibitor chemotherapy |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US11498922B2 (en) | 2017-04-07 | 2022-11-15 | ACEA Therapeutics, Inc. | Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide |
RU2811770C1 (ru) * | 2019-12-16 | 2024-01-17 | Онкобикс Ко., Лтд. | Новое замещенное дейтерием производное пиримидина и содержащая его фармацевтическая композиция |
EP4079726A4 (fr) * | 2019-12-16 | 2024-01-24 | Korea Res Inst Chemical Tech | Nouveau dérivé de pyrimidine et utilisation correspondante |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2720946C (fr) | 2008-04-07 | 2013-05-28 | Irm Llc | Composes et compositions comme inhibiteurs de la proteine kinase |
WO2010111406A2 (fr) * | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Composés et leurs utilisations thérapeutiques |
WO2010144909A1 (fr) | 2009-06-12 | 2010-12-16 | Novartis Ag | Composés hétérocycliques fondus et leurs utilisations |
TW201107329A (en) | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
MX2012005332A (es) * | 2009-11-13 | 2012-10-15 | Oscotec Inc | Inhibidores de cinasa. |
ES2365960B1 (es) * | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
WO2011146313A1 (fr) * | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Composés de pyrazolopyrimidine pour le traitement du cancer |
GB201104267D0 (en) * | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
BR112014007788A2 (pt) | 2011-10-03 | 2017-04-18 | Univ North Carolina Chapel Hill | compostos de pirrolopirimidina para tratamento do câncer |
US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
US9365556B2 (en) | 2012-03-16 | 2016-06-14 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
WO2013142817A2 (fr) | 2012-03-23 | 2013-09-26 | Dennis Brown | Compositions et procédés d'amélioration du bénéfice thérapeutique de l'indirubine et de ses analogues y compris du mésoindigo |
CN104302627A (zh) | 2012-05-22 | 2015-01-21 | 北卡罗来纳大学教堂山分校 | 用于治疗癌症的嘧啶化合物 |
GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
WO2014062774A1 (fr) | 2012-10-17 | 2014-04-24 | The University Of North Carolina At Chapel Hill | Composés pyrazolopyrimidines pour le traitement du cancer |
WO2014063068A1 (fr) | 2012-10-18 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de cycline-dépendante kinase 7 (cdk7) |
USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
EP2925752A4 (fr) | 2012-11-27 | 2016-06-01 | Univ North Carolina | Composés à base de pyrimidine utilisables à des fins de traitement du cancer |
WO2017156493A1 (fr) | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Composés, compositions et procédés |
NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
EP3057955B1 (fr) | 2013-10-18 | 2018-04-11 | Syros Pharmaceuticals, Inc. | Composes heteroaromatiques utiles dans le traitement de maladies proliferatives |
US10047070B2 (en) | 2013-10-18 | 2018-08-14 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
BR112016008060A8 (pt) | 2013-10-21 | 2020-03-17 | Genosco | composto, formulação farmacêutica, processo para preparar um composto de fórmula (i), método para preparação de um composto, uso do composto ou sal farmaceuticamente aceitável do mesmo |
CN104672214B (zh) * | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
WO2015157125A1 (fr) | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Utilisations thérapeutiques de composés pyrazolopyrimidine sélectionnés présentant une activité anti-tyrosine kinase mer |
US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
WO2015164614A1 (fr) * | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de janus kinase et leurs utilisations |
CN105272921A (zh) * | 2014-06-09 | 2016-01-27 | 江苏奥赛康药业股份有限公司 | 一种制备Ceritinib的方法及其中间体化合物 |
AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
MY191736A (en) | 2014-12-23 | 2022-07-13 | Axikin Pharmaceuticals Inc | 3,5-diaminopyrazole kinase inhibitors |
AU2015385326B2 (en) * | 2015-03-04 | 2019-04-18 | Novartis Ag | Chemical process for preparing pyrimidine derivatives and intermediates thereof |
WO2016160617A2 (fr) | 2015-03-27 | 2016-10-06 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinases cycline-dépendantes |
EP3307728A4 (fr) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases |
WO2017035354A1 (fr) * | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Composés et compositions utiles pour traiter des troubles associés au gène ntrk |
CA2996978A1 (fr) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinases cycline-dependantes |
TWI733713B (zh) | 2015-11-19 | 2021-07-21 | 美商纜圖藥品公司 | 用於治療神經促進性酪氨酸受體激酶相關之異常的化合物與組成物 |
US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
CN108934162A (zh) | 2015-12-16 | 2018-12-04 | 南方研究所 | 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法 |
US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
WO2017218843A1 (fr) | 2016-06-16 | 2017-12-21 | Denali Therapeutics Inc. | Pyrimidin-2-ylamino -1h-pyrazols comme inhibiteurs de lrrk2 destinés au traitement de troubles neurodégénératifs |
GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
EP3915985A4 (fr) * | 2019-01-18 | 2022-09-28 | Voronoi Co., Ltd. | Dérivé de pyrrolopyridine et son utilisation dans la prévention et le traitement d'une maladie liée à la protéine kinase |
CN112824420B (zh) * | 2019-11-21 | 2022-04-26 | 浙江同源康医药股份有限公司 | 用作egfr激酶抑制剂的化合物及其应用 |
CN115368366A (zh) * | 2022-08-02 | 2022-11-22 | 江苏省中医药研究院 | 嘧啶并吡唑类化合物及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005016894A1 (fr) * | 2003-08-15 | 2005-02-24 | Novartis Ag | 2, 4-pyrimidine diamines utiles dans le cadre du traitement de maladies neoplasiques, de troubles inflammatoires et de troubles du systeme immunitaire |
WO2007070872A1 (fr) * | 2005-12-15 | 2007-06-21 | Rigel Pharmaceuticals, Inc. | Inhibiteurs de kinase et leurs utilisations |
WO2008039359A2 (fr) * | 2006-09-25 | 2008-04-03 | Janssen Pharmaceutica N.V. | Inhibiteurs de pyrimidine kinase bicyclique |
WO2008073687A2 (fr) * | 2006-12-08 | 2008-06-19 | Irm Llc | Composés et compositions inhibant la protéine kinase |
WO2008081928A1 (fr) * | 2006-12-28 | 2008-07-10 | Taisho Pharmaceutical Co., Ltd. | Composé pyrazolopyridimidine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2532800C (fr) * | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Modulateurs de la proteine alk (anaplastic lymphoma kinase) et leurs methodes d'utilisation |
WO2005026129A1 (fr) * | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Derives d'aminopyrimidine a disubstitution 4,6 actifs sur le plan pharmaceutique en tant que modulateurs des proteine kinases |
EP1598343A1 (fr) * | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | Dérivés de 2-arylaminopyrimidines comme des inhibiteurs de PLK |
-
2008
- 2008-08-27 WO PCT/US2008/074472 patent/WO2009032694A1/fr active Application Filing
- 2008-08-27 AU AU2008296479A patent/AU2008296479A1/en not_active Abandoned
- 2008-08-27 WO PCT/US2008/074490 patent/WO2009032703A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005016894A1 (fr) * | 2003-08-15 | 2005-02-24 | Novartis Ag | 2, 4-pyrimidine diamines utiles dans le cadre du traitement de maladies neoplasiques, de troubles inflammatoires et de troubles du systeme immunitaire |
WO2007070872A1 (fr) * | 2005-12-15 | 2007-06-21 | Rigel Pharmaceuticals, Inc. | Inhibiteurs de kinase et leurs utilisations |
WO2008039359A2 (fr) * | 2006-09-25 | 2008-04-03 | Janssen Pharmaceutica N.V. | Inhibiteurs de pyrimidine kinase bicyclique |
WO2008073687A2 (fr) * | 2006-12-08 | 2008-06-19 | Irm Llc | Composés et compositions inhibant la protéine kinase |
WO2008081928A1 (fr) * | 2006-12-28 | 2008-07-10 | Taisho Pharmaceutical Co., Ltd. | Composé pyrazolopyridimidine |
Cited By (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8399450B2 (en) | 2006-12-08 | 2013-03-19 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US8039479B2 (en) | 2006-12-08 | 2011-10-18 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US8957081B2 (en) | 2006-12-08 | 2015-02-17 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US8372858B2 (en) | 2006-12-08 | 2013-02-12 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US8377921B2 (en) | 2006-12-08 | 2013-02-19 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
US8318702B2 (en) | 2007-07-06 | 2012-11-27 | Astellas Pharma Inc. | Di(arylamino)aryl compounds |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
US9012462B2 (en) | 2008-05-21 | 2015-04-21 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
US9212181B2 (en) | 2008-06-27 | 2015-12-15 | Celgene Avilomics Research, Inc. | Substituted 2,4-diaminopyrimidines as kinase inhibitors |
US10596172B2 (en) | 2008-06-27 | 2020-03-24 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US9409921B2 (en) | 2008-06-27 | 2016-08-09 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines as kinase inhibitors |
US8609679B2 (en) | 2008-06-27 | 2013-12-17 | Celgene Avilomics Research, Inc. | 2,4-diaminopyrimidines useful as kinase inhibitors |
US9296737B2 (en) | 2008-06-27 | 2016-03-29 | Celgene Avilomics Research, Inc. | Substituted 2,4-diaminopyrimidines as kinase inhibitors |
US10828300B2 (en) | 2008-06-27 | 2020-11-10 | Celgene Car Llc | Substituted 2,4-diaminopyrimidines as kinase inhibitors |
US8710222B2 (en) | 2008-06-27 | 2014-04-29 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US10010548B2 (en) | 2008-06-27 | 2018-07-03 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8450335B2 (en) | 2008-06-27 | 2013-05-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US9987276B2 (en) | 2008-06-27 | 2018-06-05 | Celgene Car Llc | Substituted 2,4-diaminopyrimidines as kinase inhibitors |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
WO2010007756A1 (fr) * | 2008-07-14 | 2010-01-21 | 塩野義製薬株式会社 | Dérivé de pyridine ayant une activité d'inhibition de la ttk |
US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
US9487491B2 (en) | 2009-05-08 | 2016-11-08 | Astellas Pharma Inc. | Diamino heterocyclic carboxamide compound |
WO2010128659A1 (fr) | 2009-05-08 | 2010-11-11 | アステラス製薬株式会社 | Composé de carboxamide hétérocyclique diamino |
US8969336B2 (en) | 2009-05-08 | 2015-03-03 | Astellas Pharma Inc. | Diamino heterocyclic carboxamide compound |
EP3009428A1 (fr) | 2009-05-08 | 2016-04-20 | Astellas Pharma Inc. | Composés de carboxamide hétérocycliques diamino |
US9604936B2 (en) | 2010-08-10 | 2017-03-28 | Celgene Car Llc | Besylate salt of a BTK inhibitor |
US8563568B2 (en) | 2010-08-10 | 2013-10-22 | Celgene Avilomics Research, Inc. | Besylate salt of a BTK inhibitor |
US9867824B2 (en) | 2010-11-01 | 2018-01-16 | Celgene Car Llc | Heterocyclic compounds and uses thereof |
US9238629B2 (en) | 2010-11-01 | 2016-01-19 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US11096942B2 (en) | 2010-11-01 | 2021-08-24 | Celgene Car Llc | Heterocyclic compounds and uses thereof |
US10434101B2 (en) | 2010-11-01 | 2019-10-08 | Celgene Car Llc | Heterocyclic compounds and uses thereof |
US9765038B2 (en) | 2010-11-01 | 2017-09-19 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
US9375431B2 (en) | 2010-11-01 | 2016-06-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidine compounds useful as kinase inhibtors |
US10081606B2 (en) | 2010-11-01 | 2018-09-25 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
US8975249B2 (en) | 2010-11-01 | 2015-03-10 | Celgene Avilomics Research, Inc. | Heterocyclic compounds and uses thereof |
US9868723B2 (en) | 2010-11-10 | 2018-01-16 | Celgene Car Llc | Mutant-selective EGFR inhibitors and uses thereof |
US9409887B2 (en) | 2010-11-10 | 2016-08-09 | Celgene Avilomics Research, Inc. | Mutant-selective EGFR inhibitors and uses thereof |
US8796255B2 (en) | 2010-11-10 | 2014-08-05 | Celgene Avilomics Research, Inc | Mutant-selective EGFR inhibitors and uses thereof |
CN112125884A (zh) * | 2010-12-17 | 2020-12-25 | 诺华股份有限公司 | 制备嘧啶-2,4-二胺二盐酸盐的方法 |
US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
US9364476B2 (en) | 2011-10-28 | 2016-06-14 | Celgene Avilomics Research, Inc. | Methods of treating a Bruton's Tyrosine Kinase disease or disorder |
US10799504B2 (en) | 2012-01-13 | 2020-10-13 | ACEA Therapeutics, Inc. | Heterocyclic compounds and uses as anticancer agents |
US9763949B2 (en) | 2012-01-13 | 2017-09-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
US11612602B2 (en) | 2012-01-13 | 2023-03-28 | ACEA Therapeutics, Inc. | Heterocyclic compounds and uses as anticancer agents |
US9586965B2 (en) | 2012-01-13 | 2017-03-07 | Acea Biosciences Inc. | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases |
US10596174B2 (en) | 2012-01-13 | 2020-03-24 | ACEA Therapeutics, Inc. | Pyrrolopyrimidine compounds as inhibitors of protein kinases |
US9920074B2 (en) | 2012-01-13 | 2018-03-20 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
US9540335B2 (en) | 2012-03-15 | 2017-01-10 | Celgene Avilomics Research, Inc. | Salts of an epidermal growth factor receptor kinase inhibitor |
US10005738B2 (en) | 2012-03-15 | 2018-06-26 | Celgene Car Llc | Salts of an epidermal growth factor receptor kinase inhibitor |
US11292772B2 (en) | 2012-03-15 | 2022-04-05 | Celgene Car Llc | Salts of an epidermal growth factor receptor kinase inhibitor |
US10570099B2 (en) | 2012-03-15 | 2020-02-25 | Celgene Car Llc | Salts of an epidermal growth factor receptor kinase inhibitor |
US9539255B2 (en) | 2012-03-15 | 2017-01-10 | Celgene Avilomics Research, Inc. | Solid forms of an epidermal growth factor receptor kinase inhibitor |
US9056839B2 (en) | 2012-03-15 | 2015-06-16 | Celgene Avilomics Research, Inc. | Solid forms of an epidermal growth factor receptor kinase inhibitor |
US10946016B2 (en) | 2012-03-15 | 2021-03-16 | Celgene Car Llc | Solid forms of an epidermal growth factor receptor kinase inhibitor |
US9108927B2 (en) | 2012-03-15 | 2015-08-18 | Celgene Avilomics Research, Inc. | Salts of an epidermal growth factor receptor kinase inhibitor |
US10004741B2 (en) | 2012-03-15 | 2018-06-26 | Celgene Car Llc | Solid forms of an epidermal growth factor receptor kinase inhibitor |
US9834571B2 (en) | 2012-05-05 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
WO2014006554A1 (fr) | 2012-07-03 | 2014-01-09 | Aurigene Discovery Technologies Limited | Dérivés de 3-(pyrazolyl)-1h-pyrrolo[2,3-b]pyridine en tant qu'inhibiteurs de kinase |
CN102746308A (zh) * | 2012-07-09 | 2012-10-24 | 四川大学 | 别嘌醇衍生物及其制备方法和用途 |
CN102746308B (zh) * | 2012-07-09 | 2014-12-31 | 四川大学 | 别嘌醇衍生物及其制备方法和用途 |
US8685988B2 (en) | 2012-08-06 | 2014-04-01 | Acea Biosciences, Inc. | EGFR modulators and uses thereof |
US11007197B2 (en) | 2012-08-06 | 2021-05-18 | ACEA Therapeutics, Inc. | EGFR modulators and uses thereof |
US10449196B2 (en) | 2012-08-06 | 2019-10-22 | ACEA Therapeutics, Inc. | EGFR modulators and uses thereof |
US9567342B2 (en) | 2012-11-06 | 2017-02-14 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitors |
US9206166B2 (en) | 2012-11-06 | 2015-12-08 | SHANGHAI iNSTITUTE OF MATERIA MEDICA ACADEMY OF SCIENCES | Certain protein kinase inhibitors |
US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US9549927B2 (en) | 2012-12-21 | 2017-01-24 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US9145387B2 (en) | 2013-02-08 | 2015-09-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US9561228B2 (en) | 2013-02-08 | 2017-02-07 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US9796700B2 (en) | 2013-02-08 | 2017-10-24 | Celgene Car Llc | ERK inhibitors and uses thereof |
US9504686B2 (en) | 2013-02-08 | 2016-11-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US9980964B2 (en) | 2013-02-08 | 2018-05-29 | Celgene Car Llc | ERK inhibitors and uses thereof |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US10562918B2 (en) | 2013-07-11 | 2020-02-18 | ACEA Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
US10577344B2 (en) | 2013-09-10 | 2020-03-03 | The Board Of Regents Of The University Of Texas System | Therapeutics targeting truncated adenomatous polyposis coli (APC) proteins |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
US10202364B2 (en) | 2014-08-13 | 2019-02-12 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
US10611765B2 (en) * | 2014-11-06 | 2020-04-07 | Ohio State Innovation Foundation | Pyrrolopyrimidine derivatives as Mps1/TTK kinase inhibitors |
US20190106422A1 (en) * | 2014-11-06 | 2019-04-11 | Ohio State Innovation Foundation | Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors |
US10913744B2 (en) | 2015-02-13 | 2021-02-09 | Dana-Farber Cancer Institute, Inc. | LRRK2 inhibitors and methods of making and using the same |
US20180244676A1 (en) * | 2015-02-13 | 2018-08-30 | Dana-Farber Cancer Institute, Inc. | Lrrk2 inhibitors and methods of making and using the same |
US11208696B2 (en) | 2015-04-17 | 2021-12-28 | Netherlands Translational Research Center B.V. | Prognostic biomarkers for TTK inhibitor chemotherapy |
US10533011B2 (en) | 2015-10-09 | 2020-01-14 | ACEA Therapeutics, Inc. | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
CN108473490A (zh) * | 2015-12-21 | 2018-08-31 | 癌症研究科技有限公司 | 新型吡咯并[3,2-c]吡啶-6-氨基衍生物 |
CN108473490B9 (zh) * | 2015-12-21 | 2020-12-25 | 癌症研究科技有限公司 | 吡咯并[3,2-c]吡啶-6-氨基衍生物 |
CN108473490B (zh) * | 2015-12-21 | 2020-11-13 | 癌症研究科技有限公司 | 吡咯并[3,2-c]吡啶-6-氨基衍生物 |
WO2018021826A1 (fr) * | 2016-07-26 | 2018-02-01 | 한국화학연구원 | Nouveau dérivé de pyrimidine-2,4-diamine et composition pharmaceutique pour la prévention ou le traitement du cancer contenant celui-ci comme ingrédient actif |
CN110662745B (zh) * | 2017-03-23 | 2021-08-03 | 大邱庆北尖端医疗产业振兴财团 | 吡咯并吡啶衍生物、其制备方法、和用于预防或治疗蛋白激酶相关疾病的药物组合物 |
AU2018239798B2 (en) * | 2017-03-23 | 2020-08-27 | Daegu Gyeongbuk Institute Of Science And Technology | Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases |
WO2018174650A1 (fr) * | 2017-03-23 | 2018-09-27 | 재단법인 대구경북첨단의료산업진흥재단 | Composé dérivé de pyrrolo-pyridine, son procédé de préparation et composition pharmaceutique le contenant en tant que principe actif pour la prévention ou le traitement de maladies associées à la protéine kinase |
CN110662745A (zh) * | 2017-03-23 | 2020-01-07 | 大邱庆北尖端医疗产业振兴财团 | 吡咯并吡啶衍生物、其制备方法、和包含其作为活性成分用于预防或治疗蛋白激酶相关疾病的药物组合物 |
US11117892B2 (en) | 2017-03-23 | 2021-09-14 | Daegu-Gyeongbuk Medical Innovation Foundation | Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases |
KR101896568B1 (ko) * | 2017-03-23 | 2018-09-10 | 재단법인 대구경북첨단의료산업진흥재단 | 피롤로-피리딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
WO2018183112A1 (fr) * | 2017-03-27 | 2018-10-04 | Cardurion Pharmaceuticals, Llc | Composé hétérocyclique |
US11197858B2 (en) | 2017-03-27 | 2021-12-14 | Cardurion Pharmaceuticals, Llc | Substituted amines for treating cardiac diseases |
TWI789381B (zh) * | 2017-03-27 | 2023-01-11 | 美商卡都瑞恩醫藥有限責任公司 | 雜環化合物 |
US10543212B2 (en) | 2017-03-27 | 2020-01-28 | Cardurion Pharmaceuticals, Llc | Substituted amines for treating cardiac diseases |
US11498922B2 (en) | 2017-04-07 | 2022-11-15 | ACEA Therapeutics, Inc. | Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide |
US11248003B2 (en) | 2017-12-07 | 2022-02-15 | Oncobix Co., Ltd. | Pyrimidine derivative having effect of inhibiting cancer cell growth and pharmaceutical composition containing same |
AU2018379499B2 (en) * | 2017-12-07 | 2021-03-04 | Oncobix Co., Ltd. | Novel pyrimidine derivative having effect of inhibiting cancer cell growth and pharmaceutical composition containing same |
RU2744168C1 (ru) * | 2017-12-07 | 2021-03-03 | Онкобикс Ко., Лтд. | Новое пиримидиновое производное, обладающее эффектом ингибирования роста раковых клеток, и содержащая его фармацевтическая композиция |
CN111386266A (zh) * | 2017-12-07 | 2020-07-07 | 昂科比克斯有限公司 | 具有抑制癌细胞生长作用的新型嘧啶衍生物及包含其的药物组合物 |
WO2019112344A1 (fr) * | 2017-12-07 | 2019-06-13 | 주식회사 온코빅스 | Nouveau dérivé de pyrimidine ayant pour effet d'inhiber la croissance de cellules cancéreuses, et composition pharmaceutique contenant celui-ci |
CN111386266B (zh) * | 2017-12-07 | 2023-08-04 | 昂科比克斯有限公司 | 具有抑制癌细胞生长作用的新型嘧啶衍生物及包含其的药物组合物 |
US11130752B2 (en) | 2018-09-25 | 2021-09-28 | Cardurion Pharmaceuticals, Llc | Aminopyrimidine compound |
RU2811770C1 (ru) * | 2019-12-16 | 2024-01-17 | Онкобикс Ко., Лтд. | Новое замещенное дейтерием производное пиримидина и содержащая его фармацевтическая композиция |
EP4079726A4 (fr) * | 2019-12-16 | 2024-01-24 | Korea Res Inst Chemical Tech | Nouveau dérivé de pyrimidine et utilisation correspondante |
CN111484484B (zh) * | 2020-04-13 | 2021-11-23 | 沈阳药科大学 | 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用 |
CN111484484A (zh) * | 2020-04-13 | 2020-08-04 | 沈阳药科大学 | 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用 |
Also Published As
Publication number | Publication date |
---|---|
AU2008296479A1 (en) | 2009-03-12 |
WO2009032694A1 (fr) | 2009-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009032703A1 (fr) | Composés et compositions inhibiteurs de kinase | |
KR102558066B1 (ko) | Tam 억제제로서 피롤로트리아진 화합물 | |
EP3399968B1 (fr) | Inhibiteurs sélectifs de mutants cliniquement importants de la tyrosine kinase de l'egfr | |
KR101036394B1 (ko) | 단백질 키나아제 의존성 질환 치료에 유용한 디아릴우레아 유도체 | |
CN102816162B (zh) | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 | |
CA2631775C (fr) | Derives substitues de 4-amino-pyrrolotriazine utiles dans le traitement de troubles hyperproliferatifs et de maladies associees a l'angiogenese | |
JP5702390B2 (ja) | タンパク質チロシンキナーゼ2阻害剤としてのピリミジン誘導体 | |
US8129379B2 (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
KR101432352B1 (ko) | 키나제 억제제로서의 피리미딘 유도체 | |
SG192686A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
JP2020531501A (ja) | Bcl−2阻害剤 | |
CN103012399A (zh) | 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用 | |
JP2022522153A (ja) | Btkおよびその変異体の阻害剤 | |
CA3037097C (fr) | Derives de 3- (4,5-substitue pyrimidinamine) phenyle deuteres et leurs applications | |
CN111356687B (zh) | 含嘧啶的三取代咪唑类化合物及其应用 | |
CN110437220B (zh) | 三氮唑类化合物及其应用 | |
TW201245176A (en) | New 5-alkynyl-pyridines | |
CN103570731B (zh) | 嘧啶并三环或嘧啶并四环类化合物及其药用组合物和应用 | |
JP2013528635A (ja) | ビフェニル置換1,3−ジヒドロ−ベンゾイミダゾール−2−イリデンアミン誘導体 | |
WO2022148317A1 (fr) | Composé de 2-aminopyrimidine et composition pharmaceutique le comprenant et application associée | |
WO2020192302A1 (fr) | Composé d'imidazole tri-substitué contenant de la pyrimidine et utilisation associée | |
TW201245175A (en) | New 5-alkynyl-pyridines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08798818 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08798818 Country of ref document: EP Kind code of ref document: A1 |